946593-15-3Relevant academic research and scientific papers
Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis
Santella, Joseph B.,Gardner, Daniel S.,Duncia, John V.,Wu, Hong,Dhar, Murali,Cavallaro, Cullen,Tebben, Andrew J.,Carter, Percy H.,Barrish, Joel C.,Yarde, Melissa,Briceno, Stephanie W.,Cvijic, Mary Ellen,Grafstrom, R. Robert,Liu, Richard,Patel, Sima R.,Watson, Andrew J.,Yang, Guchen,Rose, Anne V.,Vickery, Rodney D.,Caceres-Cortes, Janet,Caporuscio, Christian,Camac, Daniel M.,Khan, Javed A.,An, Yongmi,Foster, William R.,Davies, Paul,Hynes, John
, p. 7550 - 7564 (2015/02/18)
High-affinity, functionally potent, urea-based antagonists of CCR1 have been discovered. Modulation of PXR transactivation has revealed the selective and orally bioavailable CCR1 antagonist BMS-817399 (29), which entered clinical trials for the treatment of rheumatoid arthritis.
